Record Display for the EPA National Library Catalog


Main Title Monetizing the Pharmacological Benefits of Plants.
Author Principe, P. P. ;
CORP Author Environmental Protection Agency, Washington, DC. Office of Modeling, Monitoring Systems and Quality Assurance.
Publisher Apr 91
Year Published 1991
Report Number EPA/600/D-91/142;
Stock Number PB91-218958
Additional Subjects Medicinal plants ; Pharmacology ; Drug industry ; Economic analysis ; Terrestrial ecosystems ; Antineoplastic agents ; Public health ; Market value ; Biological diversity
Library Call Number Additional Info Location Last
NTIS  PB91-218958 Some EPA libraries have a fiche copy filed under the call number shown. 07/26/2022
Collation 46p
Plants have always had a major role in medicine and public health, and the pharmacological potential of plants has been one of the major reasons for preserving biodiversity. While their value has been appreciated in a qualitative sense, national policy-making, which relies on benefit-cost analyses, requires a quantitative valuation. In addition to its utility in providing a basis for estimating the economic consequences of the loss of biodiversity, the pharmacological potential of plants may also be one of the most easily estimated indicators of ecosystem value. The market value of plant-based prescription drugs in the United States in 1990 is estimated to be $15.5 billion (retail). Given current extinction rates and the estimated likelihood of developing new, marketable pharmaceutical products, the annual market benefit in the United States expected to be foregone as a result of plant extinction is about $150 million. The present value in 1991 of the foregone benefit in 2050 is about $3 billion--which includes only market value. Methodological issues related to the estimation of the economic value of plant-based pharmaceuticals are discussed, and the economic value of plant-based anti-cancer drugs is estimated.